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Ethical Aspects of Tissue Engineering: A Review
Rob B.M. de Vries, M.A., M.Sc.,1 Anke Oerlemans, M.A., M.Sc.,1 Leen Trommelmans, M.A., M.Sc.,2
Kris Dierickx, Ph.D.,2 and Bert Gordijn, Ph.D.1
Tissue engineering (TE) is a promising new field of medical technology. However, like other new technologies, it
is not free of ethical challenges. Identifying these ethical questions at an early stage is not only part of science’s
responsibility toward society, but also in the interest of the field itself. In this review, we map which ethical
issues related to TE have already been documented in the scientific literature. The issues that turn out to
dominate the debate are the use of human embryonic stem cells and therapeutic cloning. Nevertheless, a variety
of other ethical aspects are mentioned, which relate to different phases in the development of the field. In
addition, we discuss a number of ethical issues that have not yet been raised in the literature.
Introduction
Tissue engineering* (TE) is a promising new field ofmedical technology. If further developed, it might di-
minish suffering caused by tissue or organ damage and
thereby lead to longer and healthier lives.1 However, like
other new technologies, TE is not free of ethical challenges.
Identifying these ethical questions at an early stage is not
only part of science’s responsibility toward society, but also
in the interest of the field itself: it enables the field to flourish
by preventing it from investing time and money in directions
that are likely to lack societal support.
Despite high hopes, TE is still in its infancy. There are as
yet only a few clinical applications, mainly for skin, cartilage,
and bone.2,3 However, even though the field is still largely
focused on research, it is moving ever more closely to clinical
practice. The number of clinical trials is steadily rising. Now,
therefore, seems a suitable moment to reflect on the moral
implications of this technology: the field has developed far
enough to have a sufficiently clear view of the directions in
which it is heading and has not yet developed too far, so that
there is still opportunity to steer clear of undesirable direc-
tions and effects.
TE has not figured prominently in public debates, with the
notable exception of research involving the use of human
embryonic stem cells (hESCs). In this review, we map
which ethical questions related to TE have already been
documented in the scientific literature. Further, we discuss
which other issues might be raised and which issues require
closer attention.
Methods
To find articles that explicitly pay attention to ethical is-
sues raised by or directly related to TE,{ the databases
PubMed, EMBASE, and Web of Science were searched using
the following combinations of terms: ‘‘tissue engineering’’ &
ethic*, ‘‘tissue engineered’’ & ethic*, ‘‘regenerative medicine’’
& ethic*, ‘‘tissue engineering’’ & moral, ‘‘tissue engineered’’ &
moral, and ‘‘regenerative medicine’’ & moral. The search was
limited by date (published before 01-01-2008) and language
(English). Papers in which ethic* referred to the product
name Ethicon were excluded, as well as papers that con-
tained one of the above-mentioned combinations of search
terms, but in which the ethical issues discussed did not
pertain to tissue engineering=regenerative medicine. Further,
the most important journals in the field of tissue engineer-
ing and regenerative medicine—Tissue Engineering, Bio-
materials, Journal of Tissue Engineering and Regenerative
Medicine, Regenerative Medicine, and the Journal of Regenera-
tive Medicine—were searched using the keywords ethic*
and moral. These searches combined yielded 203
*We use ‘‘tissue engineering’’ (TE) in the sense of ex vivo TE. An
ex vivo tissue-engineering product typically consists of three ele-
ments: cells (human, either autologous or allogeneic, or xenogeneic),
a supporting structure (e.g., an extracellular matrix or scaffold), and
biomolecules (e.g., growth factors). Moreover, these elements are
combined in vitro before the construct is implanted in the body.
{Authors may have a different or broader conception of TE than
we do, but we take their remarks about the ethical aspects of TE into
account insofar as they apply to TE in the restricted sense in which
we use the term.
1Section Ethics, Philosophy, and History of Medicine, Scientific Institute for Quality of Healthcare, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands.
2Faculty of Medicine, Centre for Biomedical Ethics and Law, Catholic University of Leuven, Leuven, Belgium.
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papers.{ These papers were studied and classified according
to the ethical aspects of TE mentioned and to the type of
journal in which they appeared.
Results
Papers classified according to issue
Table 1 shows the 10 ethical issues§ related to TE that are
most frequently mentioned or discussed in the scientific lit-
erature. The ethical question that dominates is the use of
hESCs. About 70% of the selected articles refer to the moral
problems raised by these cells. These articles range from eth-
ical or ethically oriented papers extensively discussing issues
like the moral status of human embryos (e.g., Refs.4–18) via
scientific reviews that describe the moral opposition evoked
by hESCs as one of the disadvantages of using these cells (e.g.,
Refs.19–44) to research papers that present alternative sources
of stem cells—for example, stem cells derived from adult bone
marrow,45–49 amniotic fluid,50–52 placenta,50,53–56 or umbilical
cord (blood)57–62 or acquired through reprogramming of dif-
ferentiated cells63–66—or ways to acquire hESCs without de-
stroying (viable) embryos.67–72
A closely related topic that is also often discussed or
mentioned is therapeutic or research cloning. About 20% of
the selected articles refer to the moral problems involved in
therapeutic cloning. Some articles merely mention that
cloning is considered by many to be morally problematic
(e.g., Refs.8,15,35,37,40,42,63,65,68,69,73–75); other papers elaborate
on the ethical objections to this technique. The objections
most often discussed are the objection that the creation
of a human embryo specifically for research purposes
and its subsequent destruction contravene its moral sta-
tus,4,6,9,17,20,43,76,77 the objection that permitting therapeutic
cloning will inevitably put us on a slippery slope toward
reproductive cloning,4,9,17,20,29,43,76–78 and ethical questions
related to paid egg donation. These latter questions include
(1) the risks involved in hyperstimulation of the ovaries and
the surgical or transvaginal recovery of oocytes for women
who will not directly profit from the donation and (2) the
commodification of both oocytes and women.8,17,20,76,77,79,80
But the use of hESCs and therapeutic cloning are not
the only ethical issues mentioned in the literature. A variety
of other questions are discussed, which relate to different
phases in the development of the field of TE.
Papers classified according to phase in development
Classified according to the phase in the development of
(the field of ) TE to which they seem most relevant, the fol-
lowing ethical issues beyond the use of hESCs and thera-
peutic cloning are mentioned or discussed.
Fundamental and preclinical research. Four clusters of ethical
issues associated with this early phase in the development of
TE can be distinguished: issues related to (1) the source of
cells (to be) used in TE products, (2) the donation of cells, (3)
the use of (laboratory) animals, and (4) morally problematic
‘‘techniques.’’
(1) Embryonic stem cells are not the only cells that are
considered morally problematic because of their origin. First,
several arguments are brought forward against the use of
fetal cells,6,17,37,50,73,81–83 in particular embryonic germ cells:
the primary source of these cells is induced abortion, which
is in itself a morally controversial intervention;37,50,73
some argue that using fetal tissue from elective abortion is a
way of legitimizing abortion and this will encourage insti-
tutions to increase the number of abortions;6,73 some fear that
women might conceive specifically to obtain fetal cells via
abortion.6
Also controversial is the use of xenogeneic cells or mate-
rials for TE purposes. The main arguments mentioned are the
risk of introducing pathogenic agents (bacteria, viruses, or
other infectious agents) into humans,24,83–94 the serious im-
munological problems xenogeneic cells may cause if they are
not genetically altered or physically isolated,24,83,87,88,91 and
the public acceptability of using animal cells=tissue.87,88,91
Some people object to the introduction of animal cells=tissue
into the human body as such; others reject the use of material
from specific animal species on the basis of religious precepts
(e.g., reservations of Muslims and Jews regarding the use of
porcine cells=tissue).85
Finally, even though the use of allogeneic cells is generally
considered to be less problematic than the use of xenogeneic
cells, the immunological problems involved in the use of
these cells24,90,91,95 and the risk of disease transmission24,90,95
are sometimes mentioned as reasons against the use of this
type of cell.
(2) A second cluster of moral issues pertains to the
donation=collection of cells for TE. The requirement of ob-
taining informed consent is often stressed: donors should
be informed as fully as possible about future uses of their
tissue=cells, and no tissue=cells may be used without the
consent of the donor.4,16,81,96–103 Similarly, the impor-
tance of protecting the privacy of the donor is pointed
out, for example through the anonymization of samples
used in scientific research.16,96–98,101–105 Further, many au-
{The References section does not show all 203 articles. We were
particularly interested in ethical aspects of TE beyond the use of
embryonic stem cells and therapeutic cloning. Of the papers that
address one of these latter two issues only a selection is therefore
presented, namely, those papers in which these issues are not only
mentioned but also, to some extent, discussed.
§The objections=arguments described hereafter are not necessarily
endorsed by the authors who mention them in their paper.
Table 1. Ten Ethical Issues Most
Frequently Mentioned
Ethical issue
Number
of papersa
Use of hESCs 140
Therapeutic cloning 43
Donation: altruism vs. transfer of
property rights
16
Use of xenogeneic cells=tissue 14
Informed consent of cell donor 11
Privacy of cell donor 9
Contribution of TE to life extension 9
Ethical aspects of clinical trails 8
Private banking of umbilical cord blood 8
Use of fetal cells 8
aTotal number of selected papers: 203. Papers referring to more
than one issue are grouped under each of these issues.
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thors indicate that free and unpaid donation is or should
be the ideal behind policy=legislation regulating the collec-
tion of cells=tissues for research in regenerative medi-
cine.84,86,90,98,102,103,105,106
A closely related issue is the question of the ownership of
the human body and its parts.13,76,81,95,99–102,104,106 This
question is sometimes interpreted as a question of who has
authority over the use of collected cells=tissue,99,101 but more
often as a question of whether the human body can be
subject to property rights. Acknowledging these rights seems
a necessary condition for allowing paid donation and the
patenting not only of processes involving human (stem) cells,
but also of these cells themselves.13,16,90,102,107–109 The reasons
most often mentioned against granting property rights are
that it would violate human dignity and that it could lead to
exploitation of poor people.13,81,95,106
Moreover, there is considerable debate about the
most desirable mode of banking of umbilical cord
blood.54,99,104,110–114 Stem cells from this blood might in the
future be used for regenerative purposes. Several ethical ar-
guments are advanced for preferring public banks to private,
commercial banks that collect cord blood for autologous use.
A number of authors stress that at present it is doubtful
whether cord blood stem cells will ever be used for autolo-
gous transplantation. To claim that cord blood banking is
a way to save the key components for future medical
treatment of your child is therefore to create false
hope.99,104,110–112 This is especially problematic because the
promotional materials of these commercial banks are tar-
geted at prospective parents at a vulnerable time.104,110–112
Moreover, private banks may take cord blood out of circu-
lation that might have been collected by public banks for
allogeneic transplantation in unrelated recipients. Donating
to private banks therefore conflicts with the principle of
solidarity.99,104,112
(3) A small number of papers pay attention to the moral
justifiability of using animals either as a source of cells or for
TE research.88,115,116 Laboratory animals are used to study
the fundamental processes involved in TE, and they function
as models of human disease for testing new products. As
several authors115,116 stress, these animals can experience
substantial discomfort, and experiments should therefore
only be performed when no alternatives are available and
when the benefit of the experiment outweighs the animals’
suffering. On the other hand, several other papers point to
the prospects of using human cell cultures and TE products
like artificial skin as alternatives for laboratory animals in
safety testing or drug discovery.97,117–119
(4) Besides objections to therapeutic cloning, moral reser-
vations regarding certain other ‘‘techniques’’ are mentioned,
notably regarding the genetic engineering of cells for TE
products90,120,121 and the mixing of human and animal cells
or genetic material (e.g., the use of interspecies nuclear
transfer or the engrafting of human ES cells into a mouse
blastocyst).74,83,122,123
Clinical trials. Although an integral analysis of the ethical
aspects of clinical trials with TE products is lacking, a
number of issues are discussed. Most important among these
are the requirement of informed consent of the partici-
pant,16,124,125 the importance of and difficulties involved in
risk–benefit analysis,16,91,124 the need for clear criteria of ef-
ficacy and safety,38,86,91,126,127 and the desirability of long-
term posttrial follow-up including the establishment of a
registry.126
Clinical practice (short-term). The following issues men-
tioned in the literature seem to be particularly relevant when
TE products are introduced in clinical practice: the informed
consent of patients, especially if the product contains xeno-
geneic material;85,88,93,102 in view of public health, the
necessity of complying with the regulations of Good
Manufacturing & Laboratory Practice38,86,91,98,105 and justice
in the distribution of treatments with TE products, both
among different groups within Western societies and be-
tween these societies and developing countries.84,124,128
Advanced clinical application (long-term). Besides the issues
previously described, a number of more philosophical
questions about TE are raised. The first question can be
concisely described by slightly adapting the title of one of the
papers about stem cells31—TE: immortality or a healthy old
age? In other words, should TE only or primarily be used to
fight the negative effects of ageing or may it also be deployed
in the extension of the human lifespan?15,18,31,90,95,128–132
Second, is it morally desirable to use TE to enhance human
capabilities?124,128,133 And how will TE affect our view of and
attitude toward our body?5,81,90,128,132
Distribution among phases. In conclusion, and taking a more
quantitative perspective, the preclinical phase is dominant
not only in terms of the number of issues associated with it,
but also in terms of the number of articles that pay attention
to issues most relevant to this phase (Table 2). Even if papers
referring to the use of hESCs and therapeutic cloning are not
included, more papers pertain to the preclinical phase than
to all three later phases combined.
Papers classified according to type of journal
A large majority of the selected papers are published in
scientific=biomedical journals; only a small minority can be
found in journals in the domain of (medical) ethics, social
science, or the humanities (Table 3). Not all articles in the
biomedical journals are purely scientific; some are of a more
reflective nature. Nevertheless, by far most authors have a
scientific=biomedical affiliation.
Discussion
Even though the use of hESCs and the closely related topic
of therapeutic cloning dominate the scientific literature
dealing with the ethical aspects of TE, that does not mean
Table 2. Papers Classified According to Phase
in Development TE
Phase development TE Number of papersa
Preclinical research 55b
Clinical trials 8
Clinical practice 12
Advanced clinical application 14
aTotal number of selected papers: 203. Papers referring to more
than one issue are grouped under each of these issues.
bPapers referring to hESCs and=or cloning are not included.
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that these issues are at present most relevant from an ethical
point of view. Current applications of TE are not yet using
cells derived from hESCs, and it is unlikely that they will do
so in the near future134 (although research in this direction is
being carried out135–137). Moreover, even if TE products
based on hESCs will be developed, still many TE products
will contain other types of (stem) cells. And although there
are strong indications that it is in principle possible to ac-
quire human blastocysts through somatic cell nuclear trans-
fer,138 it is as yet far from evident that it will be possible to
obtain in a safe and efficient way differentiated cells, let
alone tissues or organs, derived from hESCs acquired via
therapeutic cloning.20,139,140 In other words, the strong focus
of the debate on the issues of hESCs and therapeutic cloning
is not warranted.
Although, apart from hESCs and therapeutic cloning, a
large number of ethical issues relevant to the development of
TE are already being mentioned in the literature, we believe
that there are significant issues that are not yet covered or
did not get the attention they deserve (cf. Refs.141–143). Some
of these issues have been discussed in relation to other new
medical technologies like cell and gene therapy, but we
consider it important that they be explicitly discussed in the
context of TE.
First, the need for obtaining informed consent from a cell
donor is greatly stressed. However, the problems involved in
meeting the ideals of informed consent are hardly discussed:
Is it possible to provide all relevant information regarding
future uses and tests? If not, will general information suf-
fice?** Will the donor be able to (fully) understand the de-
tailed and scientific information given? If not, what is his=her
consent worth?{{
Second, although the need for animal models that more
closely resemble human diseases is noted,115,123,148–150 the
significance of this fact for the justifiability of animal exper-
iments is largely ignored. Further, since the TE products that
are being developed as alternatives to laboratory animals are
not primarily intended to replace experiments for TE re-
search, it is still an open question whether the development
of TE will lead to an overall reduction of the number of
laboratory animals used.
Third, more attention needs to be paid to the ethical issues
involved in clinical trials,{{ in particular to the significance of
the complexity of TE products for dealing with these issues.
TE products are complex in at least the following three re-
spects: (1) TE products show a certain amount of variability
because they contain metabolically active cells in the dy-
namic environment of the extracellular scaffolds; (2) im-
planting a TE product initiates an ongoing interaction
between the product and the recipient’s body, which also
varies to some extent; (3) implanting a TE product is an ir-
reversible process—once the process of integration and re-
generation is initiated, it is impossible to reverse it
completely.143 This complexity seems to have consequences
for the possibility of meeting the requirements of informed
consent (cf. consent cell donation), of making an accurate
risk–benefit analysis, for the generalizability of the results of
trials and for the necessity of a long-term posttrial follow-up.
Moreover, since TE is claimed to be part of a new medical
paradigm, namely, that of regenerative medicine, it would
seem that the goal of a trial testing the efficacy of a TE
product should be to demonstrate not only that the treatment
is as effective as current treatments, but also that there is in
fact regeneration in the body.
Fourth, given that TE products will likely be rather ex-
pensive, broad access to these products will be dependent on
reimbursement. However, the lack of standards for clinical
trials and persisting uncertainty whether treatments with TE
products will not only be safe but also more effective than
current treatments decrease the likelihood that they will be
refunded. But if reimbursement were not provided, appli-
cation of these products would be the privilege of the happy
few, and all the fruits of publicly funded research would be
reaped by private hands.
Fifth, two groups of people are likely to benefit espe-
cially from TE: young people with congenital diseases, for
whom TE might provide a long-term solution superior
to any therapy currently available, and the elderly, who suffer
more than average from degenerative diseases. In the light of
the limited budgets for health care, who should profit most?
Apart from the issue of just allocation—which group is most
entitled to these treatments?—a number of other consider-
ations seem to be relevant for answering this question.§§ Thus,
although application for elderly people could significantly
increase their quality of life, this application also raises an-
thropological and socioeconomic questions. Would large-scale
application to the problems of the elderly lead to a medicali-
zation of ageing; that is, would ageing increasingly be re-
garded as a medical problem to be treated rather than as a
natural physiological condition?*** And would application to
the elderly aggravate the socioeconomic problems of an age-
ing society?{{{ Pediatric applications, on the other hand, raise
their own set of problems, for example, regarding the long-
term safety and efficacy as well as the validity of the sub-
stituted consent given by the parents.{{{
**For a similar discussion of the amount of information that is
required or desirable for informed consent regarding the collection of
tissue samples, see, for example, Refs.144,145
{{For a discussion of similar problems in the context of informed
consent for clinical trials, see, for example, Refs.146,147
{{For a general discussion of the ethical issues in clinical trials, see
Ref.151
§§Acknowledging that these considerations are of diverse ethical
nature and deserve attention in their own right, we here focus on
how they might bear on the question of who should profit most from
TE products.
***The issue of the status of the ageing process has been mainly
discussed in the context of research into the extension of the maxi-
mum human lifespan, see, for example, Refs.152,153
{{{For a general discussion of the economics and ethics of anti-
ageing interventions, see, for example, Ref.154
{{{For a general discussion of the ethical issues in neonatal sur-
gery, see, for example, Ref.155
Table 3. Papers Classified According to Type
of Journal
Type of journal
Number
of papers
Biomedical journal 190
Other (ethics, social science,
and humanities)
13
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Sixth, even though a few authors128,133 mention ethical
issues involved in using TE for enhancing the human body,
the examples they use (extending the range of our senses
or improving cognitive function for healthy individuals
through cell-based therapies) are unlikely to be realized in
the near future. An application beyond therapy that will
probably be available much sooner is the use of TE products
for cosmetic purposes (e.g., more natural breast implants; cf.
Refs.156,157). The question of the desirability of such non-
medical applications of TE needs to be addressed.§§§
Although all the above-mentioned issues are relevant
for an ethical assessment of TE, they are not equally ur-
gent. We would argue that special attention should presently
be devoted to the ethical questions related to clinical trials,
because of the stage of development of the field of TE—on
the verge from preclinical research to clinical trials—and
because of the relatively scarce attention paid to this phase
so far. Moreover, the ethical issues involved in the collec-
tion of cells (informed consent, privacy=confidentiality, and
altruistic vs. paid donation) should remain a focus of re-
flection, for without an ethically satisfactory regulation of
cell donation even preclinical research would=should come
to a halt.
The fact that so many papers in scientific=biomedical
journals pay attention to potential ethical issues related to TE
clearly indicates that tissue engineers already reflect on the
ethical aspects of their work. The involvement of profes-
sional ethicists, on the other hand, still seems relatively low.
We would argue that, to ensure an adequate identification
and analysis of the ethical aspects of TE, ethicists should
become more engaged in the ethical debate on TE. However,
to prevent the ethical reflections from becoming too abstract
or irrelevant in the light of scientific developments, close
collaboration with scientists in the field of TE is of vital im-
portance. Combining the intellectual capacities of scientists
and ethicists should lead to ethical considerations that have
both reflective depth and practical relevance.
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